An Additive Manufacturing MicroFactory : overcoming brittle material failure and improving product performance through tablet microstructure control for an immediate release dose form

Prasad, Elke and Robertson, John and Halbert, Gavin W. (2024) An Additive Manufacturing MicroFactory : overcoming brittle material failure and improving product performance through tablet microstructure control for an immediate release dose form. Polymers, 16 (18). 2566. ISSN 2073-4360 (https://doi.org/10.3390/polym16182566)

[thumbnail of Prasad-etal-Polymers-2024-An-Additive-Manufacturing-MicroFactory]
Preview
 Text. Filename: Prasad-etal-Polymers-2024-An-Additive-Manufacturing-MicroFactory.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (1MB)| Preview

Abstract

Additive manufacturing of pharmaceutical formulations offers advanced micro-structure control of oral solid dose (OSD) forms targeting not only customised dosing of an active pharmaceutical ingredient (API) but also custom-made drug release profiles. Traditionally, material extrusion 3D printing manufacturing was performed in a two-step manufacturing process via an intermediate feedstock filament. This process was often limited in the material space due to unsuitable (brittle) material properties, which required additional time to develop complex formulations to overcome. The objective of this study was to develop an additive manufacturing MicroFactory process to produce an immediate release (IR) OSD form containing 250 mg of mefenamic acid (MFA) with consistent drug release. In this study, we present a single-step additive manufacturing process employing a novel, filament-free melt extrusion 3D printer, the MicroFactory, to successfully print a previously ‘non-printable’ brittle Soluplus®-based formulation of MFA, resulting in targeted IR dissolution profiles. The physico-chemical properties of 3D printed MFA-Soluplus®-D-sorbitol formulation was characterised by thermal analysis, Fourier Transform Infrared spectroscopy (FTIR), and X-ray Diffraction Powder (XRPD) analysis, confirming the crystalline state of mefenamic acid as polymorphic form I. Oscillatory temperature and frequency rheology sweeps were related to the processability of the formulation in the MicroFactory. 3D printed, micro-structure controlled, OSDs showed good uniformity of mass and content and exhibited an IR profile with good consistency. Fitting a mathematical model to the dissolution data correlated rate parameters and release exponents with tablet porosity. This study illustrates how additive manufacturing via melt extrusion using this MicroFactory not only streamlines the manufacturing process (one-step vs. two-step) but also enables the processing of (brittle) pharmaceutical immediate-release polymers/polymer formulations, improving and facilitating targeted in vitro drug dissolution profiles.

ORCID iDs

Prasad, Elke ORCID logoORCID: https://orcid.org/0000-0002-5412-9374, Robertson, John ORCID logoORCID: https://orcid.org/0000-0002-2191-1319 and Halbert, Gavin W.;
CORE (COnnecting REpositories)